"","Num","POD","SD","%","Genes","KE"
"ELEVATED RED CELL ADENOSINE DEAMINASE LEVEL","1","3.920248957",NA,"5.56","445038","INCREASED CYCLIC ADENOSINE MONOPHOSPHATE"
"PURE RED CELL APLASIA","1","3.920248957",NA,"5","445038","N/A METHEMOGLOBINEMIA DECREASED HEMOGLOBIN HEMATOCRIT RED BLOOD CELL NUMBER"
"GO:1903009","3","23.0420012606045","0.380545298680883","8.82","321947, 445413, 436882","DECREASE GTPCH-1"
"REGULATION OF WNT SIGNALING PATHWAY","4","26.39808253793","0.234898513850976","5.06","321947, 445413, 406685, 436882","INHIBITION WNT PATHWAY"
"GO:0001775","3","26.8868077327748","0.418886682841876","1.53","321947, 445413, 336613","ACTIVATION DENDRITIC CELLS"
"TUBE FEEDING","1","39.69437256",NA,"5.88","406685","INHIBITION FEEDING"
"G TGF BETA SIGNALING PATHWAY","1","39.69437256",NA,"1.47","406685","ACTIVATION TGF-BETA PATHWAY; UP REGULATION TGFBETA1 EXPRESSION"
"GO:0019882","4","42.1279541559283","0.267344524793912","6.78","321947, 445413, 334632, 436882","GENERATION OF NOVEL EPITOPES  ANTIGEN PRESENTATION"
"CTOME CELLULAR RESPONSE TO HYPOXIA","4","53.6119876319116","0.296530593000678","9.3","321947, 445413, 436882, 337810","N/A HYPOXIA"
"GO:0016310","5","57.5779696009365","0.40462924754481","4","324947, 406600, 245701, 399483, 317763","ACTIVATION SP1"
"REGULATION OF PROTEOLYSIS","2","58.2457345731706","0.860175920589978","1.79","321947, 445027","IMPAIRED PROTEOSTASIS"
"GO:0006635","2","59.3725364214463","0.601119021767544","10","406325, 445290","DECREASED PEROXISOMAL FATTY ACID BETA OXIDATION OF FATTY ACIDS; DECREASED MITOCHONDRIAL FATTY ACID BETA OXIDATION; DECREASED MITOCHONDRIAL FATTY ACID BETA-OXIDATION; INHIBITION MITOCHONDRIAL FATTY ACID BETA-OXIDATION"
"GO:0006936","1","59.81053517",NA,"1.82","373076","REDUCTION ABDOMINAL MUSCLE CONTRACTION; OVERACTIVATION MUSCLE CONTRACTION"
"INCREASED SUSCEPTIBILITY TO FRACTURES","1","59.81053517",NA,"2.86","373076","INCREASED DISEASE SUSCEPTIBILITY"
"GO:0001508","1","82.84968945",NA,"6.67","406443","ALTERED ACTION POTENTIAL"
"GO:0004882","1","82.84968945",NA,"2.86","406443","N/A ANDROGEN RECEPTOR ANTAGONISM; AGONISM ANDROGEN RECEPTOR; DECREASED ANDROGEN RECEPTOR ACTIVITY; ACTIVATION ANDROGEN RECEPTOR"
"GO:0042447","1","82.84968945",NA,"25","406443","INCREASED T4/T3 CATABOLISM"
"REGULATION OF SODIUM ION TRANSPORT","1","82.84968945",NA,"8.33","406443","INHIBITION SODIUM CHANNEL; MODULATION SODIUM CHANNEL"
"STEROID HORMONE MEDIATED SIGNALING PATHWAY","1","82.84968945",NA,"0.98","406443","DECREASE STEROIDOGENIC ACUTE REGULATORY PROTEIN STAR; DECREASED HSD17B10 EXPRESSION; REDUCED MATURATION INDUCING STEROID PLASMA"
"GO:0004620","1","84.05124931",NA,"20","30354","INHIBITION PHOSPHOLIPASE A"
"GO:0006633","1","84.05124931",NA,"3.45","30354","SYNTHESIS DE NOVO FA; INCREASED DE NOVO FA SYNTHESIS; INCREASED DE NOVO FA SYNTHESIS"
"GO:0006954","1","84.05124931",NA,"0.85","30354","INCREASE INFLAMMATION; INCREASE INFLAMMATION CORNEAL CELLS; INFILTRATION INFLAMMATORY CELLS; INCREASED INFLAMMATION; CHRONIC COUGH RESPIRATORY IRRITABILITY"
"GO:0050663","1","84.05124931",NA,"3.33","30354","RELEASE CYTOKINE"
"ABNORMAL CIRCULATING CHOLESTEROL CONCENTRATION","1","84.05124931",NA,"9.09","30354","DECREASED CHOLESTEROL; PERTURBATION OF CHOLESTEROL"
"CHOLESTASIS","1","84.05124931",NA,"2.86","30354","INCREASED CHOLESTASIS; CHOLESTASIS PATHOLOGY"
"TRIGLYCERIDE METABOLIC PROCESS","1","84.05124931",NA,"6.25","30354","ACCUMULATION TRIGLYCERIDE"
"ABNORMAL NASAL MORPHOLOGY","7","101.136065626734","0.121290664929745","4.52","445038, 445202, 406685, 436647, 245701, 503767, 399483","INCREASE SITE OF CONTACT NASAL TUMORS"
"ABNORMAL CIRCULATING ESTROGEN LEVEL","1","105.265698",NA,"7.14","406409","INCREASED CIRCULATING ESTROGEN LEVELS"
"ABNORMAL OVARIAN MORPHOLOGY","1","105.265698",NA,"2.7","406409","PROMOTION OVARIAN GRANULAR CELL TUMORS; DECREASED OVARIAN E2; PROMOTION OVARIAN ADENOMAS"
"ABNORMALITY OF THE OVARY","1","105.265698",NA,"1.75","406409","REDUCED PROSTAGLANDINS OVARY"
"CYANOSIS","1","105.265698",NA,"5.26","406409","N/A CYANOSIS OCCURS"
"DECREASED FERTILITY","1","105.265698",NA,"1.32","406409","IMPAIRED FERTILITY; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; REDUCTION CUMULATIVE FECUNDITY AND SPAWNING; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; DECREASED TESTOSTERONE"
"GO:0046903","7","114.574989077688","0.142338012143895","3.03","321947, 445413, 30354, 393945, 336613, 563580, 266992","SUPPRESSION VLDL SECRETION; INCREASE MUCIN PRODUCTION; INCREASED SECRETION OF LOCAL GROWTH FACTORS"
"GO:0006839","6","118.717725998319","0.115642108540834","13.04","406325, 323956, 406443, 402883, 449787, 450011","REDUCTION CHOLESTEROL TRANSPORT IN MITOCHONDRIA"
"GO:0045333","2","134.177967705046","0.428809965906566","2.78","322670, 406405","INCREASE OXIDATIVE METABOLISM"
"GO:0045444","2","135.875803703555","0.147501027047702","4.88","30354, 436647","INCREASED ADIPOGENESIS"
"GO:0009790","5","137.453441902241","0.202095574834681","2.96","321947, 323956, 30343, 399483, 321928","DEFECT OF EMBRYOGENESIS"
"GO:0006629","9","139.049013063545","0.0744937708041067","4.37","406325, 445202, 406443, 30354, 393945, 445290, 450011, 393897, 64608","ALTERATION LIPID METABOLISM"
"DECREASED BODY WEIGHT","11","143.544784810715","0.0698164308523456","4.87","445038, 445202, 322670, 373076, 406409, 245701, 445290, 406405, 563392, 399483, 321928","DECREASED BODY WEIGHT"
"GO:0030163","8","146.194017331364","0.116353094937788","5.23","321947, 445413, 114445, 334632, 436882, 393897, 337810, 445027","INCREASED CATABOLISM OF MUSCLE PROTEIN"
"GO:0003824","7","154.021864226914","0.117810204211469","10.77","406325, 436930, 30497, 445290, 406405, 64608, 335974","DECREASED DHB4/HSD17B4; DECREASE INCORPORATION OF ACTIVE IODIDE INTO IODOTYROSINES; INHIBITION PROLYL HYDROXYLASES; INHIBITION UROD; DECREASE AKT/ENOS ACTIVITY; INHIBITION DEIODINASE 2; INHIBITION DEIODINASE 1; INHIBITION IODOTYROSINE DEIODINASE IYD; INHIBITION DEIODINASE 3; INHIBITION DUAL OXIDASE; INDUCTION UPREGULATION OF GLUCURONYLTRANSFERASE ACTIVITY"
"HYPERACTIVITY","2","165.315514618619","0.438112522980616","4","406685, 399483","INDUCTION ATAXIA PARALYSIS OR HYPERACTIVITY; INCREASED ATAXIA PARALYSIS OR HYPERACTIVITY; N/A ATAXIA PARALYSIS OR HYPERACTIVITY"
"RESPONSE TO NITRIC OXIDE","1","171.3608175",NA,"14.29","192295","DECREASED NITRIC OXIDE"
"RESPONSE TO ESTRADIOL","1","171.3608175",NA,"3.33","192295","REDUCTION PLASMA 17BETA-ESTRADIOL CONCENTRATIONS"
"G OOCYTE MEIOSIS","4","177.562680557119","0.15018002217548","10","406685, 406443, 245701, 406419","REDUCED MEIOTIC PROPHASE I/METAPHASE I TRANSITION OOCYTE"
"ABNORMALITY OF BLOOD AND BLOOD FORMING TISSUES","8","178.569636635236","0.109059532384967","1.98","445038, 445202, 406409, 445290, 406405, 503767, 321928, 266992","DAMAGING RED BLOOD CELLS; HEMOLYSIS"
"RESPONSE TO REACTIVE OXYGEN SPECIES","2","189.272714167666","0.0305303850433396","3.57","192295, 406600","INCREASED REACTIVE OXYGEN SPECIES"
"GO:0005102","4","196.229285583743","0.109446891120519","1.92","406443, 30354, 245701, 563392","DECREASED TESTOSTERONE BINDING TO ANDROGEN RECEPTOR HYPOTHALAMUS"
"GO:0019904","4","197.019624920751","0.0883954051318617","3.25","406443, 192295, 114445, 563392","N/A INTERFERENCES WITH SH-/SELEN-PROTEINS"
"ABNORMAL LIVER MORPHOLOGY","5","198.862894039421","0.130713592045699","4.2","445202, 30354, 445290, 503767, 399483","INDUCTION LIVER “DYSFUNCTIONAL” CHANGES BY CGA 330050; INFLAMMATION LIVER; N/A LIVER FIBROSIS; INCREASE RBC CONGESTION IN LIVER; INCREASE LIVER AND SPLENIC HEMOSIDEROSIS; REDUCTION VITELLOGENIN SYNTHESIS IN LIVER; INCREASE VITELLOGENIN SYNTHESIS IN LIVER; FORMATION LIVER FIBROSIS; FORMATION LIVER TUMOR"
"ABNORMALITY OF THE ABDOMINAL ORGANS","5","198.862894039421","0.130713592045699","2.96","445202, 30354, 445290, 503767, 399483","IMPAIRED DEVELOPMENT OF REPRODUCTIVE ORGANS"
"ABNORMALITY OF THE LIVER","5","198.862894039421","0.130713592045699","0.67","445202, 30354, 445290, 503767, 399483","INCREASED INDUCTION OF UDPGT'S IN LIVER; INCREASED LIVER STEATOSIS; INCREASED LIVER STEATOSIS; N/A HEPATOTOXICITY HEPATOPATHY INCLUDING A CONSTELLATION OF OBSERVABLE EFFECTS; INDUCTION SUSTAINED HEPATOTOXICITY"
"GO:0051899","2","205.018445260742","0.278247968596769","9.52","406443, 450011","OCCURRENCE A PAROXYSMAL DEPOLARIZING SHIFT; PROLONGED DEPOLARIZATION OF NEURONAL MEMBRANE"
"GO:0005488","42","205.181832389309","0.0215017362428418","3.9","324947, 321947, 445038, 436930, 568332, 322670, 373076, 30354, 406495, 558071, 406409, 114445, 406600, 619259, 393945, 334632, 406853, 245701, 30343, 445290, 394048, 406514, 325181, 322599, 393897, 64608, 563392, 503767, 58101, 335974, 337810, 561276, 100009659, 796388, 336613, 322126, 796380, 317763, 114420, 321928, 266992, 445027","INCREASED BINDING OF CHEMICALS TO 2U SERUM"
"GO:0046983","7","213.055222432778","0.0585297425384328","3.55","406443, 30354, 558071, 406600, 445290, 394048, 317763","DIMERIZATION AHR/ARNT; REDUCED DIMERIZATION ARNT/HIF1-ALPHA"
"GO:0048813","2","217.414219513464","0.296275662363129","15.38","406443, 393897","ABERRANT DENDRITIC MORPHOLOGY"
"GO:0007269","1","223.2231508",NA,"4","393945","OVERACTIVATION NEURONOTRANSMITTER RELEASE"
"GO:0042060","1","223.2231508",NA,"1.14","393945","FAILURE IN VASCULAR REPAIR MECHANISMS UNRESOLVED BLOOD LOSS HEMORRHAGE"
"GO:0044414","1","223.2231508",NA,"2.5","393945","SUPPRESSION IMMUNE SYSTEM"
"GO:0046562","1","233.3811995",NA,"3.7","30497","DECREASED GLUCOSE OXIDASE ENZYME ACTIVITY"
"ABNORMAL RESPIRATORY SYSTEM MORPHOLOGY","2","233.875039722973","0.418753009897558","1.36","373076, 321928","INCREASED RESPIRATORY DISTRESS/ARREST"
"ABNORMAL LUNG MORPHOLOGY","2","233.875039722973","0.418753009897558","1.56","373076, 321928","INCREASE ADENOMAS/CARCINOMAS BRONCHIOLOALVEOLAR"
"GO:0042701","2","248.296990803128","0.113886569294512","5.88","192295, 245701","DECREASED PROGESTERONE FROM CORPUS LUTEUM"
"GO:0072358","1","257.4665944",NA,"0.9","334632","ALTERED CARDIOVASCULAR DEVELOPMENT/FUNCTION"
"UPPER MOTOR NEURON DYSFUNCTION","6","260.374506276706","0.099902556678951","1.27","568332, 406409, 445290, 406405, 563392, 321928","DECREASE HISTAMINERGIC NEURON EXCITATION; OCCURRENCE CYTOPLASMIC VACUOLIZATION BILE DUCT CELL; OCCURRENCE CYTOPLASMIC VACUOLIZATION KUPFFER CELL"
"GO:0006412","6","262.29806705104","0.151509329175544","5.56","445038, 336641, 322599, 337810, 796380, 114420","ALTERED PROTEIN PRODUCTION"
"CTOME ACTIVATION OF BAD AND TRANSLOCATION TO MITOCHONDRIA","2","263.829418991719","0.355697576074422","18.18","406443, 406419","DIRECT MITOCHONDRIAL INHIBITION; MITOCHONDRIAL IMPAIRMENT"
"ABNORMALITY OF THE PITUITARY GLAND","2","269.210862781731","0.288362179653956","4.17","406409, 399483","INCREASED ADENOMAS PITUITARY"
"CYTOPLASMIC RIBOSOMAL PROTEINS","6","272.043683474464","0.152905577311855","4.17","445038, 336641, 58101, 337810, 393788, 114420","OCCURRENCE CYTOPLASMIC VACUOLIZATION PODOCYTE"
"REGULATION OF CELL DEATH","11","286.050786606845","0.0520187259995212","4.1","406325, 558071, 334632, 406853, 245701, 406514, 450011, 563392, 337810, 561276, 322126","N/A CELL INJURY/DEATH"
"POSITIVE REGULATION OF GENE EXPRESSION","5","286.252178632226","0.0984972377916432","2.76","30354, 406495, 406514, 561276, 114420","ALTERED GENE EXPRESSION"
"GO:0001816","3","306.965075522841","0.163747723299375","2.5","30354, 450011, 561276","NON-NEURONAL PRODUCTION OF TNF EPITHELIAL IRRITATION; PRODUCTION OF NERVE GROWTH FACTOR  EPITHELIAL IRRITATION; NON-NEURONAL PRODUCTION OF IL-8/CXCL1 EPITHELIAL IRRITATION"
"ELECTRON TRANSPORT CHAIN","2","310.269058148633","0.331952404710717","2.94","406409, 321928","DISRUPTION MITOCHONDRIAL ELECTRON TRANSPORT CHAIN"
"GO:0099536","4","318.812183441401","0.115501662616176","3.6","406443, 393945, 336613, 563580","DECREASED NEURONAL NETWORK FUNCTION IN ADULT BRAIN; DECREASED NEURONAL NETWORK FUNCTION IN ADULT BRAIN"
"GO:0006898","3","320.072510084265","0.0732006171797209","7.89","393945, 334632, 393897","REDUCTION VITELLOGENIN ACCUMULATION INTO OOCYTES AND OOCYTE GROWTH/DEVELOPMENT; INCREASED LDL UPTAKE"
"GO:0009611","2","336.524827482171","0.126061495315019","1.79","393945, 450011","ACCUMULATION DAMAGED MITOCHONDRIAL DNA"
"GLYCOLYSIS AND GLUCONEOGENESIS","2","355.70336474596","0.129416172075289","8.7","30497, 406405","DECREASED PCK1 EXPRESSION CONTROL POINT FOR GLYCOLYSIS/GLUCONEOGENESIS PATHWAY"
"GO:0004872","1","359.7753357",NA,"0.42","245701","ACTIVATION PXR/SXR"
"GO:0048856","1","359.7753357",NA,"8.33","245701","ALTERED NEUROANATOMY"
"APOPTOSIS","1","359.7753357",NA,"1.79","245701","INCREASED APOPTOSIS ADENOMAS/CARCINOMAS FOLLICULAR CELL"
"BREAST CANCER PATHWAY","1","359.7753357",NA,"0.88","245701","N/A BREAST CANCER"
"HUMAN THYROID STIMULATING HORMONE TSH SIGNALING PATHWAY","1","359.7753357",NA,"0.93","245701","DECREASED TRIIODOTHYRONINE T3 IN SERUM; INCREASE THYROID-STIMULATING HORMONE TSH; DECREASED THYROXINE T4 IN SERUM; INCREASED THYROID-STIMULATING HORMONE TSH"
"SANDAL GAP","1","359.7753357",NA,"20","245701","N/A GAP"
"CTOME SIGNALING BY TYPE 1 INSULIN LIKE GROWTH FACTOR 1 RECEPTOR IGF1R","1","359.7753357",NA,"7.69","245701","INCREASED IGF-1 MOUSE"
"PYRUVATE METABOLIC PROCESS","2","371.64419768076","0.142879049161445","3.57","30497, 563392","INHIBITION 4-HYDROXYPHENYL-PYRUVATE DIOXYGENASE HPPD ENZYME"
"LOW DENSITY LIPOPROTEIN RECEPTOR PARTICLE METABOLIC PROCESS","2","383.268340783512","0.122175364953568","33.33","334632, 393897","UP REGULATION LDLR LOW DENSITY LIPOPROTEIN RECEPTOR"
"ABNORMALITY OF REPRODUCTIVE SYSTEM PHYSIOLOGY","3","404.692423071411","0.170074168295072","2.91","406409, 399483, 321928","N/A IMPAIRMENT OF REPRODUCTIVE CAPACITY"
"GO:0008283","1","409.6733342",NA,"11.11","30343","PROLIFERATION CELL PROLIFERATION IN THE ABSENCE OF CYTOTOXICITY; ACTIVATION/PROLIFERATION T-CELLS; ALTERATIONS CELLULAR PROLIFERATION / HYPERPLASIA; INCREASE PROLIFERATION LEYDIG CELL; INCREASE MITOGENIC CELL PROLIFERATION HEPATOCYTES; INCREASE HYPERTROPHY AND PROLIFERATION FOLLICULAR CELL; INCREASE REGENERATIVE CELL PROLIFERATION CORNEAL CELLS; INCREASE REGENERATIVE CELL PROLIFERATION FORESTOMACH EPITHELIAL CELLS; INCREASE REGENERATIVE CELL PROLIFERATION HEPATOCYTES; INCREASE REGENERATIVE CELL PROLIFERATION UROTHELIAL CELLS; INCREASE CELL PROLIFERATION; INCREASE PROLIFERATION OF GOBLET CELLS; INCREASED HYPERTROPHY AND PROLIFERATION FOLLICULAR CELL; PROLIFERATION/CLONAL EXPANSION SMOOTH MUSCLE; INCREASED CELLULAR PROLIFERATION / HYPERPLASIA OF ACINAR CELLS; PROLIFERATION/CLONAL EXPANSION ABERRANT BASAL CELLS; INCREASED CELL PROLIFERATION MESOTHELIUM; INCREASE CELL PROLIFERATION EPITHELIAL CELLS"
"LOCOMOTORY BEHAVIOR","1","409.6733342",NA,"1.61","30343","REDUCED SWIMMING SPEED; REDUCED SWIMMING PERFORMANCE"
"GO:0007249","3","415.375486330083","0.105739123005809","6.98","114445, 563392, 337810","INHIBITION NUCLEAR FACTOR KAPPA B NF-KB"
"SYNTHESIS AND DEGRADATION OF KETONE BODIES","1","420.4324957",NA,"16.67","445290","NOT INCREASED CIRCULATING KETONE BODIES"
"CTOME SYNTHESIS OF KETONE BODIES","1","420.4324957",NA,"12.5","445290","DECREASED KETOGENESIS PRODUCTION OF KETONE BODIES; DECREASED KETOGENESIS"
"DNA DAMAGE RESPONSE","1","435.5063275",NA,"1.72","394048","INCREASED DNA DAMAGE-REPAIR"
"REGULATION OF POTASSIUM ION TRANSPORT","1","436.9338305",NA,"6.25","406514","INHIBITION ETHER-A-GO-GO ERG VOLTAGE-GATED POTASSIUM CHANNEL"
"GO:0007059","3","445.561465082816","0.116762441808977","6.82","114445, 563392, 317763","INCREASED CHROMOSOME MISSEGGREGATION"
"GO:0048870","4","449.753809494421","0.0359082216013557","2","406853, 245701, 450011, 561276","INCREASED MOTILITY"
"PEPTIDYL LYSINE MODIFICATION","3","466.864344449396","0.124937843322299","4.23","114445, 563392, 445027","N/A COVALENT BINDING TO PROTEIN POSSIBLY LYSINE RESIDUE"
"GO:0006915","1","477.1987619",NA,"3.23","140621","CHANGES/INHIBITION CELLULAR HOMEOSTASIS AND APOPTOSIS; DECREASED APOPTOSIS EPITHELIAL CELLS; INCREASED APOPTOSIS DECREASED LEYDIG CELLS"
"HEART DEVELOPMENT","2","492.013946808345","0.198878396168609","1.59","334632, 266992","ALTERED LARVAL DEVELOPMENT; IMPAIRED DEVELOPMENT"
"JNK CASCADE","2","492.900452586308","0.0966811756555983","9.09","245701, 337810","ACTIVATION JNK"
"GO:0042446","1","507.3351895",NA,"3.57","450011","INCREASE LUTEINIZING HORMONE LH; REPRESSED EXPRESSION OF STEROIDOGENIC ENZYMES"
"GO:1903008","1","507.3351895",NA,"7.69","450011","DISRUPTION LYSOSOME"
"GO:1903409","1","507.3351895",NA,"4","450011","INCREASE ROS PRODUCTION; PRODUCTION REACTIVE OXYGEN SPECIES"
"POSITIVE REGULATION OF CALCIUM ION TRANSPORT","1","507.3351895",NA,"3.12","450011","INCREASE CA++ INTRACELLULAR; INCREASED INTRACELLULAR CALCIUM OVERLOAD"
"GO:0040011","6","508.315521234035","0.0238176245983002","2.64","406853, 245701, 450011, 393897, 561276, 336613","INCREASED LOCOMOTION; INCREASED MUSCULAR WAVES IN FOOT; DECREASED LOCOMOTION"
"GLOMERULAR SCLEROSIS","1","542.1382869",NA,"7.14","406405","DECREASED GLOMERULAR FILTRATION"
"HYPERTENSION ASSOCIATED WITH PHEOCHROMOCYTOMA","1","542.1382869",NA,"14.29","406405","INCREASE HYPERTENSION"
"PARALYSIS","1","542.1382869",NA,"4.35","406405","INDUCTION SOMATIC MUSCLE PARALYSIS; INDUCTION PHARYNGEAL MUSCLE PARALYSIS"
"PSYCHOGENIC NON EPILEPTIC SEIZURE","1","542.1382869",NA,"7.69","406405","OCCURRENCE EPILEPTIC SEIZURE"
"GO:0006281","2","542.301440479495","0.0673492966524585","2.35","394048, 337810","N/A INSUFFICIENT OR INCORRECT DNA REPAIR; INCREASED INSUFFICIENT REPAIR OR MIS-REPAIR OF PRO-MUTAGENIC DNA ADDUCTS; OVERWHELMED MITOCHONDRIAL DNA REPAIR MECHANISMS; INCREASED DNA DAMAGE-REPAIR"
"GO:0007568","4","547.764833050061","0.0214178885227245","4.65","394048, 450011, 563392, 399483","ACCELERATED AGING"
"CONSTITUTIVE ANDROSTANE RECEPTOR PATHWAY","1","575.5321486",NA,"3.33","64608","SUPPRESSION CONSTITUTIVE ANDROSTANE RECEPTOR NR1L3; ACTIVATION CONSTITUTIVE ANDROSTANE RECEPTOR"
"HEMOGLOBIN METABOLIC PROCESS","1","575.5321486",NA,"16.67","64608","ALTERED REGULATION ALPHA HEMOGLOBIN"
"CTOME METABOLISM OF PORPHYRINS","1","575.5321486",NA,"33.33","64608","ACCUMULATION HIGHLY CARBOXYLATED PORPHYRINS"
"GO:0005515","2","580.749330429973","0.00579836617740372","4.26","322599, 563392","BINDING SH-/SELEN-PROTEINS; COVALENT BINDING PROTEIN"
"GO:0070265","2","586.626076442703","0.0445946631854398","18.18","450011, 561276","INCREASE TISSUE DEGENERATION NECROSIS & ATROPHY; INCREASED ONCOTIC NECROSIS"
"GO:0022414","2","602.477592060666","0.0996641761238619","5.56","394048, 317763","INCREASED REPRODUCTIVE SUCCESS"
"GO:0009058","2","619.655638448014","0.0226845639368151","28.57","64608, 335974","INCREASED TRIGLYCERIDE FORMATION; INCREASED TRIGLYCERIDE FORMATION; DECREASE TETRAHYDROBIOPTERIN; ROS FORMATION"
"IMMUNOLOGIC HYPERSENSITIVITY","2","642.99279135543","0.0209955426664953","8.7","503767, 399483","INCREASE ALLERGIC RESPIRATORY HYPERSENSITIVITY RESPONSE"
"CTOME SIGNALING BY EGFR","1","675.2849127",NA,"12.5","337810","ACTIVATION EGFR"
"CTOME REGULATED NECROSIS","1","675.2849127",NA,"4.76","337810","INCREASE NECROSIS TERMINAL BRONCHIOLAR CELLS"
"GO:0015631","1","678.3092533",NA,"5.26","561276","BINDING TUBULIN"
"MICROTUBULE POLYMERIZATION OR DEPOLYMERIZATION","1","678.3092533",NA,"10","561276","DEPOLYMERIZATION MICROTUBULE"
"GO:0044703","5","687.139554258001","0.0266168322727657","4.31","394048, 563392, 322126, 317763, 266992","N/A REPRODUCTIVE FAILURE"
"GO:0000003","6","687.364615530028","0.019839100400027","2.96","394048, 563392, 399483, 322126, 317763, 266992","REDUCED REPRODUCTIVE SUCCESS; REPRODUCTIVE FAILURE"
"GO:0048469","1","688.4910281",NA,"4.17","399483","INCREASED OOCYTE MATURATION"
"GO:0050673","1","688.4910281",NA,"1.22","399483","INCREASE REGENERATIVE CELL PROLIFERATION TUBULAR EPITHELIAL CELLS; INCREASE REGENERATIVE CELL PROLIFERATION TERMINAL BRONCHIOLAR EPITHELIAL CELLS"
"GLUCOCORTICOID RECEPTOR PATHWAY","1","688.4910281",NA,"4.17","399483","ACTIVATION GLUCOCORTICOID RECEPTOR"
"OXIDATIVE DAMAGE","1","688.4910281",NA,"5","399483","INCREASED OXIDATIVE DAMAGE"
"ABNORMALITY OF THE BLADDER","1","688.4910281",NA,"1.92","399483","REDUCED POSTERIOR SWIM BLADDER INFLATION; REDUCED ANTERIOR SWIM BLADDER INFLATION; INCREASE URINARY BLADDER CALCULI"
"GO:0007051","2","702.324934114047","0.0525728526825629","7.41","563392, 317763","DISORGANIZATION SPINDLE"
"GO:0030154","1","738.9513018",NA,"1.54","336613","DIFFERENTIATION OF MYOFIBROBLAST"
"DISRUPTION OF POSTSYNAPTIC SIGNALLING BY CNV","1","738.9513018",NA,"10","336613","REDUCTION EXCITATORY POSTSYNAPTIC POTENTIAL; GENERATION AMPLIFIED EXCITATORY POSTSYNAPTIC POTENTIAL EPSP"
"MORTALITY AGING","2","741.057644215345","0.0645857677232559","7.69","503767, 321928","REDUCED FITNESS OR EVEN MORTALITY ACIDOSIS HYPOVOLEMIC SHOCK AND ORGAN DYSFUNCTION; INCREASE MORTALITY; INCREASED MORTALITY"
"CTOME FOXO MEDIATED TRANSCRIPTION","1","840.1475345",NA,"3.57","406419","ACTIVATION FOXO"
"RENAL TUBULAR DYSFUNCTION","1","940.2296419",NA,"3.85","266992","INCREASE HYPERPLASIA RENAL TUBULAR CELLS; INCREASE CYTOTOXICITY RENAL TUBULAR CELL; INCREASE ADENOMAS/CARCINOMAS RENAL TUBULAR; OCCURRENCE RENAL PROXIMAL TUBULAR NECROSIS"
